Side-by-side research comparison of Exenatide and Semaglutide across our PubMed, ClinicalTrials.gov, and EuropePMC corpus. No direct head-to-head trials in our corpus — this comparison synthesizes indirect evidence across 14 Exenatide studies and 662 Semaglutide studies.
| Exenatide | Semaglutide | |
|---|---|---|
| Drug class | glp 1 agonist | glp 1 agonist |
| Studies in corpus | 14 | 662 |
| Highest evidence tier | meta analysis | — |
| Evidence tier mix | rct · 3 meta analysis · 1 other · 5 cohort · 1 review · 1 | n/a |
| Studies with explicit sample size | 4 | 0 |
| Head-to-head studies in corpus | 0 — indirect comparison only | |
Beyond the literature: here's what third-party Certificate-of-Analysis records (Janoshik, BCC, Auxlabs) say about real Exenatide and Semaglutide batches we've tested. Aggregate, public data — cross-reference against the studies below.
Fewer than 3 published Exenatide COA records so far — not enough for a meaningful purity aggregate yet.
We tested 2418 Semaglutide batches across 608 manufacturers, 99.66% avg purity.
Looking for vendor-level purity, endotoxin, and HPLC data on Exenatide or Semaglutide? TitrateLab tracks Certificate-of-Analysis records from the major peptide labs (Janoshik, BCC, Auxlabs) alongside the research above. Cross-reference vendor batches against the studies on this page.